Search | Clinical Trials Finder

Conditions: Bowel Preparation for Colonoscopy
Interventions: Split-dose polyethylene glycol, Morning-only polyethylene glycol; Other
Lead sponsor: Cook County Health; Government
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Colonoscopy
Interventions: polyethylene glycol 3350; Drug
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 8 Years to 18 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Gender Dysphoria
Interventions: Polyethylene Glycol 3350; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab Pegol, Placebo, Methotrexate; Biological · Other
Lead sponsor: UCB Pharma SA; Industry
Eligibility: 18 Years and older
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 70
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 63 more

Conditions: Need for Bowel Preparation
Interventions: Prepopik® ½ Sachet x 2 (9-12 years), Prepopik® 1 Sachet x 2 (9-12 years), Oral polyethylene glycol (PEG) based preparation (9-12 years), Prepopik® 1 Sachet x 2 (13-16 years), Oral polyethylene glycol (PEG) based preparation (13-16 years); Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 9 Years to 16 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 9
States / cities: Birmingham, Alabama • San Diego, California • Indianapolis, Indiana + 6 more

Conditions: B Acute Lymphoblastic Leukemia
Interventions: Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin, Doxorubicin, Echocardiography Test, Imatinib, Leucovorin, Mercaptopurine, Methotrexate, Multigated Acquisition Scan, Pegaspargase, Prednisolone, Prednisone, Radiation Therapy, Thioguanine, Vincristine; Procedure · Biological · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 366 Days to 46 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 143
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 121 more

Conditions: Colonoscopy
Interventions: BLI4700, Polyethylene glycol bowel preparation; Drug
Lead sponsor: Braintree Laboratories; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 23
States / cities: Mobile, Alabama • Tucson, Arizona • Anaheim, California + 20 more

Conditions: Colorectal Cancer Screening
Interventions: PillCam® COLON 2 procedure-CONTROL, Senna tablets, PEG, Metoclopramide, Erythromycin, SUPREP oral sulfate solution, Bisacodyl, SUPREP oral sulfate solution with Gastrografin; Device · Drug
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Anniston, Alabama • Indianapolis, Indiana • Dayton, Ohio + 2 more

Conditions: Injury of Other Nerves at Wrist and Hand Level of Unspecified Arm, Initial Encounter
Interventions: Polyethylene Glycols; Drug
Lead sponsor: WellSpan Health; Other
Eligibility: 16 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: York, Pennsylvania

Conditions: Line Insertion Site, Central Line-associated Bloodstream Infection (CLABSI)
Interventions: Povidone-Iodine, Chlorhexidine gluconate, Pluronic Cream, control; Drug · Other
Lead sponsor: University of Virginia; Other
Eligibility: Up to 7 Days
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Colonoscopy
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 5 Years to 21 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Dry Eye Disease (DED)
Interventions: Preservative Free Polyethylene glycol 400 0.25%, Propylene Glycol (0.6%), Carboxymethylcellulose sodium 0.5%, Glycerin 1.0%, Polysorbate 80 0.5%; Drug
Lead sponsor: Andover Research Eye Institute; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Rochester, New York

Conditions: HIV Infections
Interventions: Peginterferon alfa-2b; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 16 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 15
States / cities: Long Beach, California • Los Angeles, California • San Francisco, California + 11 more

Conditions: Ophthalmic Solutions
Interventions: F# 13418-148 Eye Drops, F#13418-158 Eye Drops, F# PF-004390 Eye Drops; Drug
Lead sponsor: Johnson & Johnson Consumer Inc. (J&JCI); Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Varicose Veins
Interventions: Polidocanol (1%) Microfoam (Varisolve), Endovenous Microfoam Occlusion; Drug · Procedure
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 7
States / cities: Los Angeles, California • Durham, North Carolina • Winston-Salem, North Carolina + 4 more

Conditions: Crohn's Disease
Interventions: Certolizumab pegol, Azathioprine; Biological · Drug
Lead sponsor: Gastroenterology Research of America; Other
Eligibility: 18 Years to 70 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hepatocellular Carcinoma
Interventions: ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol), Placebo, Best Supportive Care; Drug · Other
Lead sponsor: Polaris Group; Industry
Eligibility: 18 Years and older
Enrollment: 636 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 21
States / cities: Birmingham, Alabama • Coronado, California • La Jolla, California + 16 more

Conditions: Primary Progressive Multiple Sclerosis
Interventions: Idebenone, placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Preparation for Colonoscopy
Interventions: Gatorade/Miralax, NuLytely, Bisacodyl, Placebo; Drug
Lead sponsor: Gastroenterology Services, Ltd.; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Downers Grove, Illinois

Conditions: Constipation
Interventions: Polyethylene Glycol 3350; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Female only
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Bowel Preparation
Interventions: CLENPIQ, MIRALAX, SENNA; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 12 Months to 8 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Mobile, Alabama • San Diego, California • Baltimore, Maryland

Conditions: Constipation
Interventions: Methylnaltrexone, Senna, docusate sodium, bisacodyl, magnesium hydroxide, Miralax; Drug
Lead sponsor: Shriners Hospitals for Children; Other
Eligibility: 12 Years to 21 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Moderate and Severe Active Rheumatoid Arthritis, Active Psoriatic Arthritis, Active Ankylosing Spondylitis, Moderately to Severely Active Crohn's Disease
Interventions: e-Device; Drug
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 22
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 15 more

Search by objective public record fields.

Comparison of Two Methods of Bowel Preparation for Colonoscopy in Hospitalized Patients

Short Course, Single-dose PEG 3350 for Colonoscopy Prep in Children

Polyethylene-glycol Assisted Nerve Repair in Phalloplasty

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis

Efficacy and Safety of Prepopik® in Children for Overall Colon Cleansing in Preparation for Colonoscopy

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

A Safety and Efficacy Comparison of BLI4700 Bowel Prep Versus an FDA-approved Comparator in Adults Prior to Colonoscopy

Optimization of the Bowel Preparation Regimen for the PillCam® COLON 2 Capsule Endoscopy Procedure

Conversion of Seddon III Nerve Injury to Seddon I/II Nerve Injury

Umbilical Cord Care for the Prevention of Colonization

The Efficacy Side Effects and the Tolerance of Polyethylene Glycol 3350 as a Bowel Prep in Children

Randomized Single Center Study to Evaluate Tolerability, Symptoms, and Visual Functional Outcomes With the Use of OTC Lubricating Eye Drops in Subjects With Dry Eye Disease

Certolizumab and Lower Extremity Lymph Flow in Rheumatoid Arthritis (RA)

Safety, Tolerability, and Anti-HIV Activity of PEG-Intron in HIV-Positive Children

A Study to Evaluate the Efficacy of Investigational OTC Eye Drops

Safety Study of Varisolve® Procedure for Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt

Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease

Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy

Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)

Gatorade/Miralax With or Without Bisacodyl Versus NuLytely for Colonoscopy Preparation

Bowel Function After Minimally Invasive Hysterectomy

Study Assessing CLENPIQ as Bowel Preparation for Pediatric Colonoscopy

Methylnaltrexone Use for Opioid-induced Postoperative Constipation

Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease